MarketInOut Stock Screener Log In | Sign Up

PhotoCure ASA

OSL • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 10/30/2026
PhotoCure ASA stock price and volume chart

Company Profile

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeOSL
Market Capitalization1,335.06 mln
Float24.72 mln
Earnings Date10/28/2026

EPS

2.91
Solid

P / E

15.96
Moderately valued

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

-1.96
Caution advised

Relative Strength

19 / 100
Significantly lagging

Debt / Equity

0.02
Debt-free

Business Description

Photocure ASA is a Norwegian pharmaceutical company founded in 1993 and headquartered in Oslo, focused on improving the detection and treatment of cancer. Its main product, Hexvix/Cysview, helps doctors identify bladder cancer more accurately during examination procedures. The company also has a drug-device treatment in development for cervical disease, and works with several partners to expand its reach across Europe, North America, and beyond. Photocure sells through wholesalers, pharmacies, and hospitals, and continues to explore new technologies, including AI-based tools for cancer diagnostics.

Key Fundamentals

EPS2.91
P/E15.96
ROE14.94
RPS25.36
ROIC38.47
ROA10.43
Interest Cover5.99
EBITDA, mln167
EV / EBITDA7.16
EV / EBIT8.63
Revenue, mln679
EV / Revenue1.77

Quote Details

Last 46.45
Change -0.25 (-0.54%)
Open 46.85
Volume 75,384
Turnover 3,501,587
Average Volume 56,912

Financial Ratios

Pre-Tax Profit Margin14
Leverage Ratio1.49
Current Ratio3.65
Price / Book2.23
Price / Tangible Book11.46
Price / Cash Flow13.66
Price / Free Cash Flow17.64
Debt / Equity0.02
Price / Sales1.98
PEG Ratio14.90

Financial Strength

Altman Z-Score4.5
Piotroski F-Score 7 / 9
Beneish M-Score-1.96
Price to Intrinsic Value1.35
Price to Graham Number2.95

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.2% 12 / 100   
1 Month -4.62% 33 / 100   
2 Months -18.22% 14 / 100   
6 Months -30.36% 14 / 100   
1 Year -13.34% 27 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog